A promising drug delivery candidate (CS-g-PMDA-CYS-fused gold nanoparticles) for inhibition of multidrug-resistant uropathogenic Serratia marcescens

Nanoparticle-mediated therapeutic management in cholangiocarcinoma drug targeting: Current progress and future prospects

Patients with cholangiocarcinoma (CCA) often have an unfavorable prognosis because of its insidious nature, low resectability rate, and poor response to anticancer drugs and radiotherapy, which makes early detection and treatment difficult. At present, CCA has a five-year overall survival rate (OS) of only 5%, despite advances in therapies. New an increasing number of evidence suggests that nanoplatforms may play a crucial role in enhancing the pharmacological effects and in reducing both short- and long-term side effects of cancer treatment. This document reviews the advantages and shortcomings of nanoparticles such as liposomes, polymeric nanoparticle，inorganic nanoparticle, nano-metals and nano-alloys, carbon dots, nano-micelles, dendrimer, nano-capsule, bio-Nanomaterials in the diagnosis and treatment of CCA and discuss the current challenges in of nanoplatforms for CCA.

Mechanisms of Metallic Nanomaterials to Induce an Antibacterial Effect

Pathogenic microorganisms, including bacteria, are becoming resistant to most existing drugs, which increases the failure of pharmacologic treatment. Therefore, new nanomaterials were studied to spearhead improvement against the same resistant pathogenic bacteria. This has increased the mortality in the world population, principally in under-developed countries. Moreover, recently there has been research to find new drug formulations to kill the most dangerous microorganisms, such as bacteria cells which should avoid the spread of disease. Therefore, lately, investigations have been focusing on nanomaterials because they can exhibit the capacity to show an antibacterial effect. These studies have been trying oriented in their ability to produce an improvement to get antibacterial damage against the same pathogenic bacteria resistance. However, there are many problems with the use of nanoparticles. One of them is understanding how they act against bacteria, "their mechanism(s) action" to induce reduction or even kill the bacterial strains. Therefore, it is essential to understand the specific mechanism(s) of each nanomaterial used to observe the interaction between bacteria cells and nanoparticles. In addition, since nanoparticles can be functionalized with different antibacterial drugs, it is necessary to consider and distinguish the antibacterial activity of the nanoparticles from the antibacterial activity of the drugs to avoid confusion about how the nanoparticles work. Knowledge of these differences can help better understand the applications of the primary nanoparticles (i.e., Ag, Au, CuO, ZnO, and TiO², among others) described in detail in this review which are toxic against various bacterial strains.

Spatiotemporally co-delivery of triple therapeutic drugs via HA-coating nanosystems for enhanced immunotherapy

There is growing empirical evidence that certain types of chemotherapy and phototherapy trigger immunogenic cell death and enhance the therapeutic anticancer efficacy of genetic immunotherapy. However, the main challenge is spatiotemporally co-delivering different drugs to maximize the therapeutic index of the combination therapy. In this study, a drug delivery system (HTCP-Au/shPD-L1/DOX) was designed with a polysaccharide-wrapped shell and a condensed DNA core. To construct the HTCP-Au vector, dodecyl side chains with a polyethylenimine (PEI) head were grafted onto hyaluronic acid, and AuNPs were grafted via Au-S bonds. During drug loading, PEI arrested shRNA plasmid DNA targeting programmed cell death ligand 1 (shPD-L1) via electrostatic interactions. It also formed a PEI-DNA core that was automatically enclosed when aliphatic hydrocarbons pulled the hyaluronic acid backbone. A hydrophobic interlayer consisting of dodecyl bridge chains between the PEI-DNA core and the hyaluronic acid shell was required to accommodate hydrophobic doxorubicin. In vitro and in vivo assays demonstrated that this core-shell drug delivery system could efficiently load and transport three different drugs and effectively target tumors. Moreover, it could activate the immune system, thereby providing promising therapeutic efficacy against tumor growth and metastasis.